# MucoLox Formulation to Mitigate Mucositis Symptoms in Head/Neck Cancer

> **NCT03461354** · NA · TERMINATED · sponsor: **Wake Forest University Health Sciences** · enrollment: 49 (actual)

## Conditions studied

- Mucositis Oral
- Head and Neck Cancer

## Interventions

- **OTHER:** MucoLox
- **OTHER:** Sodium Bicarbonate

## Key facts

- **NCT ID:** NCT03461354
- **Lead sponsor:** Wake Forest University Health Sciences
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-09
- **Primary completion:** 2024-04-01
- **Final completion:** 2024-04-01
- **Target enrollment:** 49 (ACTUAL)
- **Why stopped:** Interim analysis indicated study closure
- **Last updated:** 2025-02-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03461354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03461354, "MucoLox Formulation to Mitigate Mucositis Symptoms in Head/Neck Cancer". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT03461354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*